HC Wainwright Issues Optimistic Estimate for MLYS Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Research analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for shares of Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.90) per share for the quarter, up from their previous forecast of ($1.13). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.50) EPS, FY2026 earnings at ($3.23) EPS, FY2027 earnings at ($3.46) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at $1.36 EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02.

A number of other analysts have also recently issued reports on the stock. Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. The Goldman Sachs Group cut their price target on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, February 13th.

Mineralys Therapeutics Trading Down 8.4 %

Mineralys Therapeutics stock opened at $12.40 on Monday. Mineralys Therapeutics has a 12-month low of $8.24 and a 12-month high of $18.38. The firm has a market capitalization of $778.53 million, a price-to-earnings ratio of -3.41 and a beta of -0.39. The firm has a 50 day moving average of $11.90 and a 200 day moving average of $12.29.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $97,888.70. Following the completion of the transaction, the chief financial officer now owns 226,097 shares of the company’s stock, valued at $2,057,482.70. This represents a 4.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $15.76, for a total value of $878,950.96. Following the completion of the sale, the insider now directly owns 116,704 shares in the company, valued at $1,839,255.04. This trade represents a 32.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 84,861 shares of company stock valued at $1,142,937 in the last three months. 33.24% of the stock is currently owned by corporate insiders.

Institutional Trading of Mineralys Therapeutics

Hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Mineralys Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock worth $130,000 after purchasing an additional 989 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Mineralys Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company’s stock worth $2,645,000 after buying an additional 1,307 shares during the last quarter. Northern Trust Corp raised its position in shares of Mineralys Therapeutics by 0.7% during the 4th quarter. Northern Trust Corp now owns 246,113 shares of the company’s stock valued at $3,030,000 after buying an additional 1,688 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Mineralys Therapeutics by 2.7% in the 4th quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company’s stock valued at $804,000 after acquiring an additional 1,711 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Mineralys Therapeutics by 19.1% in the fourth quarter. Wells Fargo & Company MN now owns 23,714 shares of the company’s stock worth $292,000 after acquiring an additional 3,802 shares in the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.